This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shulman, H. M. Articles by Storb, R. Search for Related Content PubMed PubMed Citation Articles by Shulman, H. M. Articles by Storb, R.

American Journal of Pathology, Vol 126, 114-125, Copyright © 1987 by American Society for Investigative Pathology

REGULAR ARTICLES

Induction of hepatic veno-occlusive disease in dogs [published erratum appears in Am J Pathol 1987 Apr;127(1):following 198]

HM Shulman, K Luk, HJ Deeg, WB Shuman and R Storb

The authors attempted to induce hepatic veno-occlusive disease (VOD) in 64 dogs. Preparative treatments included combinations of total-body irradiation (TBI) or localized hepatic irradiation (LI) or both and chemotherapy consisting of dimethylbusulfan (DMB), L-phenylalanine mustard (L-PAM), methotrexate, or monocrotaline. VOD occurred infrequently in those dogs given 9.2 Gy TBI and DMB (1/10), TBI and/or LI (9.2-27 Gy) with L-PAM (2/36) or high dose methotrexate and LI (0/2). Specifically, VOD occurred in the dogs with a shorter interval between TBI and DMB or in the dog that received the glutathione reductase inhibitor, buthionine sulfoximide (BSO) before L-PAM. In contrast, among 17 dogs given monocrotaline, 8 developed VOD, particularly when used with L-PAM +/- irradiation (7/13). The major cause of death, early gastrointestinal toxicity, was further augmented by higher doses of irradiation, by shortening the interval between LI and L-PAM administration to less than 4 weeks, and administering BSO or monocrotaline before L-PAM. Gastrointestinal toxicity was lessened by giving low dose cyclophosphamide given before L-PAM. VOD can be produced in dogs especially with monocrotaline or BSO given before and L-PAM +/- irradiation. However, gastrointestinal toxicity renders the study of VOD beyond the acute phase difficult. Nevertheless, this approach appears useful for the study of VOD in other animals and for developing agents aimed at preventing VOD.

This article has been cited by other articles:

				J. Bouligand, A. Deroussent, N. Simonnard, P. Opolon, J. Morizet, E. Connault, E. Daudigeos, M. Re, A. Paci, and G. Vassal Induction of Glutathione Synthesis Explains Pharmacodynamics of High-Dose Busulfan in Mice and Highlights Putative Mechanisms of Drug Interaction Drug Metab. Dispos., February 1, 2007; 35(2): 306 - 314. [Abstract] [Full Text] [PDF]

				R. Qiu, T. F. Kalhorn, and J. T. Slattery ABCC2-Mediated Biliary Transport of 4-Glutathionylcyclophosphamide and Its Contribution to Elimination of 4-Hydroxycyclophosphamide in Rat J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1204 - 1212. [Abstract] [Full Text] [PDF]

				E. Savier, D. Azoulay, E. Huguet, F. Lokiec, M. Gil-Delgado, and H. Bismuth Percutaneous Isolated Hepatic Perfusion for Chemotherapy: A Phase 1 Study Arch Surg, March 1, 2003; 138(3): 325 - 332. [Abstract] [Full Text] [PDF]

				G. B. McDonald, J. T. Slattery, M. E. Bouvier, S. Ren, A. L. Batchelder, T. F. Kalhorn, H. G. Schoch, C. Anasetti, and T. Gooley Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation Blood, March 1, 2003; 101(5): 2043 - 2048. [Abstract] [Full Text] [PDF]

				C. R Jonas, A. B Puckett, D. P Jones, D. P Griffith, E. E Szeszycki, G. F Bergman, C. E Furr, C. Tyre, J. L Carlson, J. R Galloway, et al. Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients Am. J. Clinical Nutrition, July 1, 2000; 72(1): 181 - 189. [Abstract] [Full Text] [PDF]